Asston Pharmaceuticals Ltd
Established in 2019, Asston Pharmaceuticals Limited is engaged in the manufacturing and export of pharmaceutical formulations and nutraceutical products under the “Asston” brand.[1]
- Market Cap ₹ 106 Cr.
- Current Price ₹ 124
- High / Low ₹ 130 / 113
- Stock P/E 24.4
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 50.3 %
- ROE 67.8 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 56.1%
Cons
- Company has high debtors of 235 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 9.60 | 6.54 | 15.59 | 25.04 | |
| 9.96 | 5.02 | 13.04 | 18.87 | |
| Operating Profit | -0.36 | 1.52 | 2.55 | 6.17 |
| OPM % | -3.75% | 23.24% | 16.36% | 24.64% |
| 0.96 | 0.65 | 0.25 | 0.57 | |
| Interest | 0.43 | 0.72 | 0.93 | 0.95 |
| Depreciation | 0.01 | 0.04 | 0.05 | 0.09 |
| Profit before tax | 0.16 | 1.41 | 1.82 | 5.70 |
| Tax % | 31.25% | 25.53% | 25.27% | 24.04% |
| 0.11 | 1.06 | 1.36 | 4.33 | |
| EPS in Rs | 1.57 | 15.14 | 17.35 | 6.90 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 38% |
| TTM: | 61% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 240% |
| TTM: | 218% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 56% |
| Last Year: | 68% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 0.78 | |
| Reserves | 0.23 | 1.29 | 5.61 | |
| 3.31 | 5.24 | 6.82 | ||
| 5.25 | 6.46 | 7.05 | ||
| Total Liabilities | 9.49 | 13.69 | 20.26 | |
| 0.92 | 1.13 | 1.09 | ||
| CWIP | 0.00 | 0.00 | 0.00 | |
| Investments | 0.00 | 0.00 | 0.00 | |
| 8.57 | 12.56 | 19.17 | ||
| Total Assets | 9.49 | 13.69 | 20.26 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -1.19 | -0.32 | -3.80 | -0.16 | |
| 0.00 | -0.91 | -0.01 | 0.87 | |
| 1.29 | 1.21 | 3.69 | -0.51 | |
| Net Cash Flow | 0.10 | -0.01 | -0.12 | 0.19 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 243.33 | 480.53 | 378.11 | |
| Inventory Days | 27.24 | 204.29 | 63.48 | |
| Days Payable | 246.78 | 754.51 | 256.12 | |
| Cash Conversion Cycle | 23.79 | -69.70 | 185.47 | |
| Working Capital Days | 77.94 | 234.96 | 268.07 | |
| ROCE % | 37.14% | 26.91% |
Documents
Annual reports
No data available.
Business Model[1][2]
The company has a diversified model involving:
- Direct manufacturing and marketing of its products
- Contract manufacturing/loan licensing for third-party marketers
- Export sales primarily to African markets